MASCC Score (Febrile Neutropenia Risk)
Predicts risk of serious complications in febrile neutropenia. MASCC score >=21 identifies low-risk patients eligible for outpatient oral antibiotic management.
Score interpretation
→ Hospital admission; IV broad-spectrum antibiotics within 1h (piperacillin-tazobactam or cefepime); blood cultures x2; MRSA cover if line/colonisation; antifungals if fever persists >96h; haematology/oncology review
→ Oral ciprofloxacin + amoxicillin-clavulanate (or co-amoxiclav); consider 24h observation then discharge with close outpatient follow-up; blood cultures; return if deteriorates; oncology review
Interpretation bands for the MASCC Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Meropenem (Paediatric) · Carbapenem — Severe / MDR Gram-Negative Infections / Febrile Neutropenia
- Piperacillin-Tazobactam (Burns — Sepsis) · Antibiotic — Extended-Spectrum Penicillin + Beta-Lactamase Inhibitor
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.